ACE and COVID-19: The case for Nln is perhaps more strengthened by lack of strong evidence that angiotensin receptor blockers (ARBs) are better tolerated in COVID‐19 patients than ACE inhibitors (these drugs would further lower activity of ACE and hence result in increased levels of bradykinin) (Sparks et al., 2020; Speth, 2020).